KBC Group NV increased its stake in Orthofix International N.V. (NASDAQ:OFIX) by 34.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,576 shares of the medical device company’s stock after buying an additional 9,471 shares during the period. KBC Group NV owned approximately 0.20% of Orthofix International N.V. worth $1,700,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in OFIX. State of Alaska Department of Revenue raised its stake in Orthofix International N.V. by 79.3% in the second quarter. State of Alaska Department of Revenue now owns 3,551 shares of the medical device company’s stock valued at $165,000 after buying an additional 1,571 shares in the last quarter. Mason Street Advisors LLC bought a new stake in Orthofix International N.V. during the first quarter valued at approximately $159,000. Municipal Employees Retirement System of Michigan bought a new stake in Orthofix International N.V. during the second quarter valued at approximately $196,000. Quantbot Technologies LP bought a new stake in Orthofix International N.V. during the first quarter valued at approximately $175,000. Finally, BNP Paribas Arbitrage SA raised its stake in Orthofix International N.V. by 68.9% in the first quarter. BNP Paribas Arbitrage SA now owns 4,656 shares of the medical device company’s stock valued at $178,000 after buying an additional 1,900 shares in the last quarter. Institutional investors and hedge funds own 94.43% of the company’s stock.

Orthofix International N.V. (OFIX) opened at 48.06 on Wednesday. The stock’s 50 day moving average price is $46.23 and its 200 day moving average price is $41.75. The firm has a market capitalization of $873.25 million, a P/E ratio of 112.55 and a beta of 0.25. Orthofix International N.V. has a 52 week low of $32.51 and a 52 week high of $49.60.

Orthofix International N.V. (NASDAQ:OFIX) last issued its earnings results on Monday, August 7th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.01. The company had revenue of $108.90 million for the quarter, compared to analysts’ expectations of $102.94 million. Orthofix International N.V. had a net margin of 1.88% and a return on equity of 9.96%. Orthofix International N.V.’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.41 EPS. On average, equities analysts expect that Orthofix International N.V. will post $1.57 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “KBC Group NV Buys 9,471 Shares of Orthofix International N.V. (OFIX)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/30/kbc-group-nv-buys-9471-shares-of-orthofix-international-n-v-ofix.html.

Several research firms have commented on OFIX. Zacks Investment Research upgraded Orthofix International N.V. from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a research report on Thursday, August 10th. BidaskClub upgraded Orthofix International N.V. from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. Jefferies Group LLC restated a “buy” rating and issued a $55.00 price objective (up previously from $50.00) on shares of Orthofix International N.V. in a research report on Thursday, August 10th. TheStreet upgraded Orthofix International N.V. from a “c+” rating to a “b-” rating in a research report on Tuesday, August 8th. Finally, Langenberg & Company restated a “buy” rating and issued a $53.25 price objective on shares of Orthofix International N.V. in a research report on Wednesday, June 14th. Seven investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus target price of $52.75.

In other news, CEO Brad Mason sold 2,733 shares of the company’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $48.10, for a total value of $131,457.30. Following the sale, the chief executive officer now directly owns 188,053 shares of the company’s stock, valued at approximately $9,045,349.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Raymond Fujikawa sold 6,364 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $47.06, for a total transaction of $299,489.84. Following the completion of the sale, the insider now directly owns 31,084 shares in the company, valued at $1,462,813.04. The disclosure for this sale can be found here. 5.60% of the stock is currently owned by corporate insiders.

Orthofix International N.V. Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Want to see what other hedge funds are holding OFIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orthofix International N.V. (NASDAQ:OFIX).

Institutional Ownership by Quarter for Orthofix International N.V. (NASDAQ:OFIX)

Receive News & Stock Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related stocks with our FREE daily email newsletter.